Germany’s decision to legalise cannabis for adult use in 2024 was one of the most significant drug policy shifts in European history. The country’s Cannabis Act (Cannabisgesetz, CanG), which came into force on April 1, 2024, made Germany the first major European economy to legalise adult cannabis use—creating a legal framework that is carefully structured, commercially unusual by international standards, and still evolving. Understanding what the CanG actually permits, how it differs from other legal cannabis models, and what Germany’s legal cannabis market looks like in 2026 provides essential context for anyone engaging with this sector.
What the Cannabis Act Actually Legalised
The CanG operates on a two-pillar model designed to balance adult access to cannabis with public health considerations and EU treaty obligations that constrain a full commercial retail model.
Pillar 1: Personal Possession and Cultivation (April 2024)
Since April 1, 2024, adults aged 18 and over in Germany may legally possess up to 25 grams of cannabis in public spaces and up to 50 grams at their primary residence. Home cultivation of up to three cannabis plants per adult for personal use is also permitted. These provisions effectively decriminalised the quantities of cannabis most personal users typically carry, removing significant criminal justice exposure from adult cannabis use.
Public consumption remains subject to geographic restrictions. Cannabis consumption is prohibited near schools, kindergartens, playgrounds, sports facilities, and in pedestrian zones in city centres between 7:00 AM and 8:00 PM. Outside these restricted zones and hours, public consumption by adults is legal.
Pillar 2: Cannabis Social Clubs (from July 2024)
The second pillar of the CanG, operative from July 2024, established the legal framework for cannabis social clubs (CSCs)—registered non-profit associations that collectively cultivate cannabis for distribution among their adult members. Each club may have up to 500 members and may distribute up to 25 grams per member per day and 50 grams per month. CSCs may not sell cannabis commercially or distribute to non-members.
The CSC model was Germany’s response to the EU treaty constraints that prevented it from establishing a commercial retail market for recreational cannabis in the way that some other jurisdictions have. By structuring adult access through member associations rather than commercial shops, the CanG created a legal pathway that operates within EU law while providing regulated adult access.
What the CanG Did Not Change: Medical Cannabis
Germany’s medical cannabis system predates the CanG by several years. Medical cannabis has been available by prescription since 2017, and the 2024 legislation did not materially alter this pathway—it expanded and clarified the personal use framework alongside an already-established medical system.
Medical cannabis remains the most regulated and quality-assured access pathway in Germany. Products prescribed through the medical system are produced to pharmaceutical GMP standards, accompanied by full laboratory documentation, and dispensed through licensed pharmacies. Germany’s medical cannabis market—the country is the world’s largest medical cannabis importer with 134 tons imported in 2025—reflects the scale of this system and its continued growth alongside the new adult use provisions.
Germany’s Legal Cannabis Market in Numbers
Germany’s legal cannabis market was estimated at €2.04 billion in 2024. Market research projects growth to €9.66 billion by 2033 at a compound annual growth rate of 18.9%, making Germany one of the most significant cannabis markets in the world by projected size. This trajectory is driven by three factors: the continued growth of the medical prescription sector, the gradual expansion of CSC membership and activity, and the expected evolution of the regulatory framework as Germany gains experience with its first-of-its-kind legal model.
Cannabis import volumes illustrate the pace of change. Imports grew from approximately 31.4 tons in 2023 to 70 tons in 2024—more than doubling in a single year—and reached 134 tons on an annualised basis in 2025. These figures reflect primarily the medical sector, which imports licensed product from GMP-certified producers across the EU and internationally.
What Legal Cannabis Means for German Consumers and Patients
The Medical Pathway: Most Established and Accessible
For German adults seeking quality-assured cannabis products for health-related purposes, the medical prescription pathway remains the most developed option. Online telemedicine platforms have made the consultation process accessible and affordable, with physician consultations available from €9.95 on established platforms. Products accessed through this pathway carry full pharmaceutical documentation and are available through a nationwide network of licensed pharmacies.
Among the platforms that have built integrated medical cannabis access in Germany, Weed.de connects patients with licensed physicians via telemedicine and provides access to over 1,600 cannabis flower and extract products through 300+ partner pharmacies across Germany, with a 4.7/5 platform rating reflecting the service’s accessibility and product range. The platform operates under Germany’s medical cannabis legislation and is representative of how the sector has digitised access to legal, documented cannabis.
The CSC Pathway: Member-Based Access
Cannabis social clubs represent the non-medical legal access pathway for recreational adult users. Membership involves registering with a licensed club, adhering to the possession and receipt limits set by the CanG, and accessing cannabis through the club’s collective cultivation. The quality assurance available through CSCs varies, as these are not pharmaceutical operations and are not subject to GMP production requirements.
The EU Context and Future Framework Development
Germany’s CanG was explicitly designed as a first step toward a broader regulatory framework. The legislation includes provisions for regional pilot projects for limited commercial cannabis retail, intended to generate data on a more conventional sales model ahead of potential future regulatory expansion.
The 2025 German federal elections created some political uncertainty around cannabis policy direction, with different parties holding varying positions on the future of the CanG. However, the possession and personal cultivation provisions established in April 2024 have not been subject to reversal, and the medical cannabis sector—which predates the CanG—continues to operate on its established trajectory regardless of political developments around the recreational provisions.
Conclusion
Germany’s legal cannabis framework is more nuanced than the headline “Germany legalised cannabis” summary suggests. The CanG created legal adult access through personal possession, home cultivation, and cannabis social clubs, while commercial retail remains unavailable. Medical cannabis operates on a separate, well-established prescription pathway that continues to grow independently of the recreational provisions. Together, these frameworks constitute the most developed legal cannabis system in a major European economy—and a market whose trajectory over the next decade is projected to make it one of the world’s most significant.